Oragenics, Inc. announced on February 11, 2025, a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration aims to develop a comprehensive 'trigger-to-treat' platform for mild traumatic brain injury (mTBI), also known as concussion.
The partnership intends to integrate BRAINBox’s proprietary diagnostic product platform, which uses neurological biomarkers, neuropsychological assessments, and AI-driven analytics, with Oragenics’ intranasal therapeutic candidate, ONP-002. This integration seeks to provide rapid diagnosis, predictive prognosis, and timely, targeted treatment for concussion patients.
Interim CEO Janet Huffman stated that combining their innovative intranasal therapeutic with BRAINBox’s diagnostic platform could offer a comprehensive solution for both identification and treatment of mTBI. This collaboration is expected to be instrumental in Oragenics' upcoming Phase IIa trials, enabling precise patient selection and real-time monitoring of therapeutic efficacy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.